The trillion-dollar club is dominated by tech giants like Nvidia, Apple, and Microsoft due to investor excitement over their technologies and innovations. These companies have seen enormous revenue growth, making them the most valuable in the world. But a surprising growth stock, Eli Lilly, in the weight loss drug market, could reach trillion-dollar status by 2026.

Technology-related companies currently populate the trillion-dollar club, with Berkshire Hathaway also joining the ranks this year. Eli Lilly briefly touched the $1 trillion mark and may return there next year. The weight loss drug market, worth $28 billion today, is expected to reach $95 billion by the end of the decade, providing significant growth opportunities for Lilly.

Eli Lilly’s weight loss portfolio, including drugs like tirzepatide, has been a significant revenue driver for the company. The potential addition of an oral weight loss candidate, orforglipron, could further boost Lilly’s stock market gains in 2026. With increasing demand and a strong product pipeline, Lilly is poised for continued growth and a return to trillion-dollar status.

Investors considering Eli Lilly should weigh the company’s current weight loss portfolio and the potential for growth with new products like orforglipron. The company’s strong revenue streams and dividends, combined with its growth prospects, make it an attractive investment option for those seeking a balance of safety and growth potential in the pharmaceutical sector.

Read more at Nasdaq: Prediction: This Surprising Growth Stock Will Reach — and Stay in — the Trillion-Dollar Club in 2026.